Demographic characteristics of the study population (n = 83) followed up for neurodevelopmental assessments compared with those who died (n = 60) or were lost to follow-up (n = 8)
| Characteristic | Followed Up (n = 83) | Not Followed Up (n = 68) | P Value |
|---|---|---|---|
| GA (median) (IQR) (wk) | 26.3 (24.5–28.4; 23.1–31.5) | 24.3 (23.3–26.6; 22.3–31.5) | <.001 |
| BW (median) (IQR) (g) | 890 (680–1200; 481–1985) | 730 (606–1016; 420–2020) | .015 |
| Male sex | 46 (55.4%) | 37 (54.4%) | .901 |
| IUGR | 4 (4.8%) | 7 (10.3%) | .223 |
| Multiple birth | 16 (19.5%) | 11 (16.4%) | .626 |
| Inborn | 72 (86.7%) | 63 (92.6%) | .241 |
| Maternal antenatal steroids | |||
| None | 11 (13.3%) | 12 (17.6%) | .720 |
| Incomplete | 34 (41.0%) | 28 (41.2%) | |
| Complete | 38 (45.8%) | 28 (41.2%) | |
| MgSO4 | 22 (26.5%) | 15 (22.1%) | .527 |
| Maternal chorioamnionitis | 22 (26.5%) | 10 (14.7%) | .078 |
| Pneumothorax | 13 (15.7%) | 16 (23.5%) | .222 |
| Inotropic agent | 13 (15.7%) | 15 (22.1%) | .314 |
| EOS | 11 (13.3%) | 7 (10.3%) | .577 |
| PDA treated | 49 (59.0%) | 28 (41.2%) | .029 |
| NEC | 3 (3.6%) | 1 (1.5%) | .414 |
| Postnatal steroids | 41 (49.4%) | 27 (39.7%) | .234 |
| ROP treated | 4 (4.8%) | 1 (1.5%) | .379 |
Note:—IQR indicates interquartile range; IUGR, intrauterine growth restriction; MgSO4, magnesium sulfate; PDA, patent ductus arteriosus; NEC, necrotising enterocollitis; EOS, early onset sepsis; ROP, retinopathy of prematurity.